학력 및 경력사항

• 연세대학교 대학원 의학박사
• 연세대학교 의과대학 졸업

• 2024-현재  | 이화여자대학교 의과대학 교수
• 2011-2024  | 가톨릭대학교 의과대학 교수, 백혈병센터장
• 2005-2011  | 가톨릭대학교 의과대학 부교수
• 2004-2005  | Fred Hutchinson Cancer Research Center (Seattle, WA, USA), Visiting Investigator
• 2000-2004  | 가톨릭대학교 의과대학 조교수
• 1997-2000  | 이화여자대학교 의과대학 전임강사
• 1996-1997  | 연세대학교 의과대학 부속 세브란스병원 혈액내과 전임의
• 1992-1996  | 연세대학교 의과대학 부속 세브란스병원 내과 전공의

• 2018 | 대한조혈모세포이식학회 학술상
• 2013 | 대한조혈모세포이식학회 최우수연제상
• 2011 | 가톨릭대학교 최우수논문상
• 2010 | 아시아-태평양조혈모세포이식학회 최우수연제상
• 2010 | 대한조혈모세포이식학회 최우수논문상
• 2008 | 대한조혈모세포이식학회 최우수연제상
• 2007 | 대한조혈모세포이식학회 최우수연제상
• 2006 | 대한혈액학회 우수연구자상
• 2004 | 서울시의사회 유한의학상 '대상'
• 2004 | 대한조혈모세포이식학회 최우수논문상
• 2002 | 대한혈액학회 LG-혈액학 학술상
• 2000 | 대한혈액학회 최우수논문상

• 2017-2021  | 대한조혈모세포이식학회 법제이사
• 2015-2018  | 대한혈액학회 성인급성림프모구성백혈병연구회 위원장
• 2014-2018  | 보건복지부 신의료기술평가위원
• 2009-2013  | 대한조혈모세포이식학회 총무이사
• 2009-2013  | 한국근로복지공단 자문위원
• 2007-2013  | 대한면역저하감염학회 학술위원장
• 2008-2010  | 대한내과학회 기획위원
• 2007-2010  | 대한혈액학회 학술위원
• 2005-2007  | 대한조혈모세포이식학회 학술위원
• 2004-2011  | 한국조혈모세포은행협회 학술위원
• 2003-2007  | 대한조혈모세포이식학회 보험위원
• 2002-2006  | 한국식품의약품안정청 중앙약사심의위원
• 2001-2004  | 대한조혈모세포이식학회 편집위원
• 1998-2001  | 대한혈액학회 편집위원
• 1996-2004  | 한국조혈모세포은행협회 이식조정위원
• 1996-현재  | 유럽혈액학회 정회원
• 1996-현재  | 미국혈액학회 정회원

•  Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia.  Bone Marrow Transplant. 2024-10. 
•  Beneficial effects of cellular immunotherapy in the prevention and treatment of posttransplant hematologic relapse of myelodysplastic neoplasms.  Ann Hematol. 2024-11. 
•  Analysis of retinal and choroidal microvascular changes using optical coherence tomography and optical coherence tomography angiography in patients with acute leukemia.  Graefes Arch Clin Exp Ophthalmol. 2024-10. 
•  The Impact of Histologic Portal T-Cell Density on the Clinical Outcomes in Hepatic Graft-versus-Host Disease and Autoimmune Liver Diseases.  Diagnotics (Basel). 2024-08. 
•  Impact of an antimicrobial stewardship programme on antibiotic utilization and resistance burden in patients with acute leukaemia: an 11-year longitudinal cohort study using interrupted time-series analysis.  J Antimicrob Chemother. 2024-08. 
•  Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.  Bone Marrow Transplant. 2024-06. 
•  Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy.  Korean J Intern Med. 2024-01. 
•  Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score-matched cohort analysis.  Ther Adv Hematol. 2023-05. 
•  Cytogenetic and molecular characteristics and outcomes of adult patients with early T-cell precursor acute lymphoblastic leukemia.  Eur J Haematol. 2023-02. 
•  Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML.  Front Oncol. 2023-11. 
•  The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma.  Sci Rep. 2023-10. 
•  Cytomegalovirus infection after allogeneic hematopoietic cell transplantation under 100-day letermovir prophylaxis: a real-world 1-year follow-up study.  Viruses. 2023-09. 
•  Efficacy of inhaled tiotropium add-on to budesonide/formoterol in patients with bronchiolitis obliterans developing after hematopoietic stem cell transplantation.  Respir Med. 2023-11. 
•  Efficacy of ex vivo purging with CD34+ selection to maximize the effects of autologous stem cell transplantation in peripheral T-cell lymphoma patients.  Cytotherapy. 2023-12. 
•  A successful bridge therapy combining hypomethylating agents with venetoclax for adult patients with newly diagnosed or relapsed/refractory acute myeloid leukemia.  Cancers (Basel). 2023-05. 
•  Haploidentical versus double-cord blood stem cells as a second transplantation for relapsed acute myeloid leukemia.  Cancers (Basel). 2023-01. 
•  Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality.  Ther Adv Hematol. 2022-02. 
•  Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.  Int J Hematol. 2022-01. 
•  Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.  Blood Cancer J. 2022-12. 
•  Correlates of quality of life in South Korean patients undergoing hematopoietic stem cell transplantation based on the symptom management model.  Sci Rep. 2022-11. 
•  Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients.  Cancers (Basel). 2022-09. 
•  Long-term treatment outcome of Castleman's disease: A real-world experience.  Front Oncol. 2022-08. 
•  Treatment for relapsed acute promyelocytic leukemia: what is the best post-remission treatment?.  Blood Res. 2022-09. 
•  Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification.  Cancers (Basel). 2022-06. 
•  A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML).  Ther Adv Hematol. 2022-03. 
•  Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma.  Front Oncol. 2022-01. 
•  Prediction and recommendation by machine learning through repetitive internal validation for hepatic veno-occlusive disease/sinusoidal obstruction syndrome and early death after allogeneic hematopoietic cell transplantation.  Bone Marrow Transplant. 2022-04. 
•  Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia According to First-Line Intravenous Immunoglobulin Response.  Acta Haematol. 2022-05. 
•  Geriatric assessment predicts non-fatal toxicities and survival for intensively treated older adults with AML.  Blood. 2022-05. 
•  Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy.  Ther Adv Hematol. 2021-12. 
•  Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.  Am J Hematol. 2021-11. 
•  Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia.  Bone Marrow Transplant. 2021-08. 
•  Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1.  Bone Marrow Transplant. 2021-07. 
•  Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission.  Bone Marrow Transplant. 2021-04. 
•  Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11.  Bone Marrow Transplant. 2021-11. 
•  Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome.  Ther Adv Hematol. 2021-09. 
•  Natural-killer cell cytotoxicity as a diagnostic and prognostic marker for adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective phase II observational study.  Ther Adv Hematol. 2021-05. 
•  Integrative Analysis of Gene Expression Data by RNA Sequencing for Differential Diagnosis of Acute Leukemia: Potential Application of Machine Learning.  Front Oncol. 2021-08. 
•  Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients.  Transplant Cell Ther. 2021-09. 
•  Comparable Outcomes Between Unrelated and Haploidentical Stem Cell Transplantation in Adult Patients With Severe Aplastic Anemia. Transplantation.  Transplantation. 2021-05. 
•  The factors influencing clinical outcomes after leukapheresis in acute leukaemia.  Sci Rep. 2021-05. 
•  The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.  Korean J Intern Med. 2021-03. 
•  Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1-RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1-RUNX1T1.  Cancers (Basel). 2021-01. 
•  Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study.  Am J Hematol. 2021-01. 
•  Development and validation of a comorbidity index for predicting survival outcomes after allogeneic stem cell transplantation in adult patients with acute leukemia: a Korean nationwide cohort study.  Blood Res. 2021-09. 
•  Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation.  Ther Adv Hematol. 2020-07. 
•  Efficacy and safety of high-dose budesonide/formoterol in patients with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplant.  J Thorac Dis. 2020-08. 
•  Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells.  Exp Hematol Oncol. 2020-09. 
•  Prognostic factors of cytomegalovirus retinitis after hematopoietic stem cell transplantation.  PLoS One. 2020-09. 
•  Comparison of Myeloablative (CyTBI, BuCy) versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Pretransplant Low WT1 Expression.  Biol Blood Marrow Transplant. 2020-11. 
•  Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis.  Ther Adv Hematol. 2020-06. 
•  Outcomes of Haploidentical Stem Cell Transplantation using Total Body Irradiation (600 cGy) and Fludarabine with Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia: A Prospective Phase II Study.  Biol Blood Marrow Transplant. 2020-10. 
•  Effects of Hormone Replacement Therapy on Bone Mass After Allogeneic Hematopoietic Stem Cell Transplantation.  J Clin Endocrinol Metab. 2020-09. 
•  Specific donor HLA allotypes as predictors of cytomegalovirus disease risk in acute myeloid leukemia.  HLA. 2020-10. 
•  Non-myeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies.  Eur J Haematol. 2020-10. 
•  Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.  Yonsei Med J. 2020-06. 
•  Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients.  Int J Endocrinol. 2020-05. 
•  Use of intrapulmonary administration of thrombin in hematological malignancy patients with alveolar haemorrhage: A case series.  Medicine (Baltimore). 2020-05. 
•  Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.  Ann Hematol. 2020-05. 
•  Comparison of HLA-matched sibling and unrelated donor transplantation in adult patients with acquired severe aplastic anemia.  Bone Marrow Transplant. 2020-08. 
•  Role of pretransplant anti-thymocyte globulin in matched sibling donor stem cell transplantation after reduced intensity conditioning for myelodysplastic syndrome.  Eur J Haematol. 2020-05. 
•  Excellent outcomes of hematopoietic stem cell transplantation with total nodal irradiation and antithymocyte globulin conditioning in severe aplastic anemia with advanced age and/or severe comorbidity.  Bone Marrow Transplant. 2020-07. 
•  Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.  Cancer. 2019-03. 
•  Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.  Cancer Med. 2019-12. 
•  Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.  Cancer Med. 2019-11. 
•  Reactivation and dynamics of cytomegalovirus and Epstein-Barr virus after rabbit antithymocyte globulin and cyclosporine for aplastic anemia.  Eur J Haematol. 2019-10. 
•  Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.  Ann Hematol. 2019-07. 
•  Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.  Clin Lymphoma Myeloma Leuk. 2019-06. 
•  Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia.  Cancer Med. 2019-02. 
•  Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy.  Haematologica. 2019-02. 
•  Autologous hematopoietic cell transplantation using dose-reduced intravenous busulfan, melphalan, and thiotepa for high-risk or relapsed lymphomas.  Bone Marrow Transplant. 2019-02. 
•  Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome.  Biol Blood Marrow Transplant. 2019-01. 
•  Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party.  Ann Hematol. 2019-01. 
•  Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia.  Clin Chim Acta. 2019-01. 
•  Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia.  Sci Rep. 2019-08. 
•  Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation.  J Immunother Cancer. 2019-02. 
•  CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia.  Exp Mol Med. 2019-01. 
•  Alteration of the Intestinal Microbiota by Broad-Spectrum Antibiotic Use Correlates with the Occurrence of Intestinal Graft-versus-Host Disease.  Biol Blood Marrow Transplant. 2019-10. 
•  WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.  Biol Blood Marrow Transplant. 2019-10. 
•  Changes in trabecular bone score and bone mineral density following allogeneic hematopoietic stem cell transplantation.  Bone. 2019-07. 
•  Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.  Dig Dis Sci. 2019-10. 
•  A case of central nervous system graft-versus-host disease following allogeneic stem cell transplantation.  Int J Hematol. 2019-11. 
•  Predictive Role of Circulating Immune Cell Subtypes Early after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia.  Int J Stem Cells. 2018-12. 
•  Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents.  Blood Res. 2018-06. 
•  Low frequency of CD3(+)CD4(+)CD161(+) T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment.  Ann Hematol. 2018-11. 
•  Optimal conditioning regimen for haplo-identical stem cell transplantation in adult patients with acquired severe aplastic anemia: Prospective de-escalation study of TBI and ATG dose.  Am J Hematol. 2018-11. 
•  Successful outcomes of second hematopoietic stem cell transplantation with total nodal irradiation and ATG conditioning for graft failure in adult patients with severe aplastic anemia.  Bone Marrow Transplant. 2018-10. 
•  Comparison of transplant-specific prognostic scoring systems in haploidentical transplantation for myelodysplastic syndrome.  Eur J Haematol. 2018-08. 
•  Cytomegalovirus Colitis during Dasatinib Treatment for Patients with Hematologic Malignancy: Case Series and Literature Review.  Infect Chemother. 2018-02. 
•  Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents.  Blood Res. 2018-06. 
•  Association of MICA and MICB polymorphisms with the susceptibility of leukemia in Korean patients.  Blood Cancer J. 2018-06. 
•  Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults.  Biol Blood Marrow Transplant. 2018-08. 
•  Prognostic Prediction Model for Second Allogeneic Stem-Cell Transplantation in Patients With Relapsed Acute Myeloid Leukemia: Single-Center Report.  Clin Lymphoma Myeloma Leuk. 2018-04. 
•  Matrix Metalloproteinase-9 in Monocytic Myeloid-Derived Suppressor Cells Correlate with Early Infections and Clinical Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation.  Biol Blood Marrow Transplant. 2018-01. 
•  Circulating CD3(+)CD4(+)CD161(+) Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma.  Biomed Res Int. 2018-01. 
•  Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia.  Blood Res. 2017-03. 
•  Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma.  Immune Netw. 2017-04. 
•  Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.  Clin Lymphoma Myeloma Leuk. 2017-09. 
•  Outcomes of allogeneic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria with or without aplastic anemia.  Eur J Haematol. 2017-04. 
•  Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.  Biol Blood Marrow Transplant. 2017-09. 
•  Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types.  Oncotarget. 2017-08. 
•  Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy.  Oncotarget. 2017-09. 
•  High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study.  J Hematol Oncol. 2017-10. 
•  BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors.  Haematologica. 2017-05. 
•  The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population.  PLoS One. 2017-03. 
•  Practical informativeness of short tandem repeat loci for chimerism analysis in hematopoietic stem cell transplantation.  Clin Chim Acta. 2017-03. 
•  Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation?.  Biol Blood Marrow Transplant. 2017-04. 
•  Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.  Bone Marrow Transplant. 2017-04. 
•  Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.  Hematol Oncol. 2017-05. 
•  Characteristics and Survival Outcome Analysis of Extramedullary Involvement in Adult Patients With t(8;21) Acute Myeloid Leukemia.  Clin Lymphoma Myeloma Leuk. 2017-01. 
•  Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.  Oncotarget. 2017-07. 
•  Clinical significance of pre-transplant circulating CD3+ CD4+ CD161+ cell frequency on the occurrence of neutropenic infections after allogeneic stem cell transplantation.  Transpl Infect Dis. 2017-02. 
•  Enhanced differentiation of mesenchymal stromal cells by three-dimensional culture and azacitidine.  Blood Res. 2017-01. 
•  Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.  Ann Oncol. 2016-06. 
•  Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission.  Oncotarget. 2016-07. 
•  Comparable outcomes between younger (⩽40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning.  Bone Marrow Transplant. 2016-11. 
•  Negative impact of unidirectional host-versus-graft killer cell immunoglobulin-like receptor ligand mismatch on transplantation outcomes after unmanipulated haploidentical peripheral blood stem cell transplantation for acute myeloid leukemia.  Biol Blood Marrow Transplant. 2016-02. 
•  Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.  Cancer Immunol Immunother. 2016-08. 
•  Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.  Respir Res. 2016-01. 
•  Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: a Korean single-center, retrospective clinical study.  Korean J Intern Med. 2016-05. 
•  Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies.  Hepatol Res. 2016-07. 
•  Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.  Bone Marrow Transplant. 2015-03. 
•  Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome.  J Hematol Oncol. 2015-08. 
•  Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients.  Thromb Res. 2015-05. 
•  Determination of posaconazole concentration with LC-MS/MS in adult patients with hematologic malignancy.  Clin Chim Acta. 2015-05. 
•  Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations.  Genes Chromosomes Cancer. 2015-08. 
•  Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.  Korean J Intern Med. 2015-03. 
•  Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation.  Bone Marrow Transplant. 2015-08. 
•  SOCS1 and SOCS3 are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation.  Blood Res. 2015-01. 
•  Genetic and epigenetic alterations of bone marrow stromal cells in myelodysplastic syndrome and acute myeloid leukemia patients.  Stem Cell Res. 2015-02. 
•  Tuberculosis before hematopoietic stem cell transplantation in patients with hematologic diseases: report of a single-center experience.  Transpl Infect Dis. 2015-01. 
•  CD161(+) T cells as predictive markers for acute graft-versus-host disease.  Biol Blood Marrow Transplant. 2015-03. 
•  Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes.  Biol Blood Marrow Transplant. 2015-03. 
•  Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.  Biol Blood Marrow Transplant. 2015-02. 
•  Equivalent outcome of autologous stem cell transplantation and reduced intensity conditioning stem cell transplantation in acute myeloid leukemia patients with t(8;21).  Acta Haematol. 2015-03. 
•  A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.  Biol Blood Marrow Transplant. 2015-01. 
•  Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma.  Ann Hematol. 2015-03. 
•  PBSC vs BM grafts with myeloablative conditioning for unrelated donor transplantation in adults with high-risk ALL.  Bone Marrow Transplant. 2014-06. 
•  Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.  Bone Marrow Transplant. 2014-12. 
•  Bone marrow plasma cell assessment before peripheral blood stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation.  Biomed Res Int. 2014-01. 
•  Similar outcomes of peripheral blood stem cells vs. bone marrow for human leukocyte antigen-matched unrelated donor transplantation in adult patients with acute myeloid leukemia using risk-adapted graft-versus-host disease prophylaxis.  Eur J Haematol. 2014-01. 
•  Validation of Western common recurrent chromosomal aberrations in Korean chronic lymphocytic leukaemia patients with very low incidence.  Hematol Oncol. 2014-04. 
•  Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation.  Transpl Int. 2014-07. 
•  Chromosome abnormalities in T-cell acute lymphoblastic leukemia in Korea.  Int J Hematol. 2014-03. 
•  Four cases of chronic myelogenous leukemia in mixed phenotype blast phase at initial presentation mimicking mixed phenotype acute leukemia with t(9;22).  Ann Lab Med. 2014-01. 
•  Influence of ex vivo purging with CliniMACS CD34(+) selection on outcome after autologous stem cell transplantation in non-Hodgkin lymphoma.  Br J Haematol. 2014-04. 
•  Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation? .  Biol Blood Marrow Transplant. 2014-01. 
•  Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma.  Ann Hematol. 2014-04. 
•  Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia.  Leuk Lymphoma. 2014-01. 
•  A fatal spontaneous gas gangrene due to clostridium perfringens during neutropenia of allogeneic stem cell transplantation: case report and literature review.  Infect Chemother. 2014-03. 
•  Cytomegalovirus appendicitis with concurrent bacteremia after chemotherapy for acute leukemia.  Korean J Intern Med. 2014-05. 
•  Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.  Am J Hematol. 2013-08. 
•  The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma.  Blood Res. 2013-03. 
•  Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status.  Am J Hematol. 2013-12. 
•  Posaconazole treatment in Korea: single-center experience over 5 years.  Yonsei Med J. 2013-05. 
•  Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA? .  Bone Marrow Transplant. 2013-12. 
•  BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.  Eur J Haematol. 2013-02. 
•  Normal karyotype mosaicism in adult AML patients with adverse-risk and undefined karyotype: preliminary report of treatment outcomes after hematopoietic stem cell transplantation.  Int J Hematol. 2013-06. 
•  Expression of SOCS1 and SOCS3 genes in human graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.  Blood Res. 2013-01. 
•  Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia.  Biol Blood Marrow Transplant. 2013-06. 
•  Impact of pre-transplant marrow blasts on survival of allogeneic stem cell transplantation in adult acute myeloid leukemia.  Int J Hematol. 2013-05. 
•  Clinical characteristics and the usefulness of the QuantiFERON-TB Gold In-Tube test in hematologic patients with hepatic or splenic lesions.  Korean J Intern Med. 2013-02. 
•  Superior transplantation outcomes of 8/8-matched unrelated donors as well as matched siblings to autologous transplantation for acute myeloid leukemia with intermediate cytogenetics in first remission.  Eur J Haematol. 2013-05. 
•  The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study.  Ann Hematol. 2013-06. 
•  Impact of cytomegalovirus gastrointestinal disease on the clinical outcomes in patients with gastrointestinal graft-versus-host disease in the era of preemptive therapy.  Ann Hematol. 2013-04. 
•  Variant of ETV6/ABL1 gene is associated with leukemia phenotype.  Acta Haematol. 2013-02. 
•  Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.  Ann Hematol. 2013-04. 
•  Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.  Acta Haematol. 2013-02. 
•  Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure.  Bone Marrow Transplant. 2013-05. 
•  Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes.  Eur J Haematol. 2013-02. 
•  Risk and prognostic factors for acute GVHD based on NIH consensus criteria.  Bone Marrow Transplant. 2013-04. 
•  Infectious complications following allogeneic stem cell transplantation: reduced-intensity vs. myeloablative conditioning regimens.  Transpl Infect Dis. 2013-01. 
•  Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.  Leukemia. 2012-11. 
•  Prognosis of invasive pulmonary aspergillosis in patients with hematologic diseases in Korea.  Tuberc Respir Dis (Seoul). 2012-03. 
•  Prognostic factors in critically ill patients with hematologic malignancies admitted to the intensive care unit.  J Crit Care. 2012-06. 
•  Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia.  Biol Blood Marrow Transplant. 2012-10. 
•  Lymphocyte subset analysis for the assessment of treatment-related complications after autologous stem cell transplantation in multiple myeloma.  Cytotherapy. 2012-04. 
•  Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.  Biol Blood Marrow Transplant. 2012-07. 
•  Circulating IL-17 levels during the peri-transplant period as a predictor for early leukemia relapse after myeloablative allogeneic stem cell transplantation.  Ann Hematol. 2012-03. 
•  Phenotypic and genetic characterization of adult T-cell acute lymphoblastic leukemia with del(9)(q34);SET-NUP214 rearrangement.  Ann Hematol. 2012-02. 
•  The first case of acute lymphoblastic leukemia with the e19a2 BCR-ABL1 transcript: imatinib therapy followed by unrelated donor transplantation induces a durable molecular response.  Leukemia. 2011-02. 
•  Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia.  Leuk Lymphoma. 2011-12. 
•  Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities.  Eur J Haematol. 2011-06. 
•  Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients.  Mycoses. 2011-06. 
•  Reduced-intensity conditioning regimen combined with low-dose total body irradiation in the treatment of myelodysplastic syndrome.  Acta Haematol. 2011-01. 
•  Vitamin B12-responsive pancytopenia mimicking myelodysplastic syndrome.  Acta Haematol. 2011-04. 
•  Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.  Eur J Haematol. 2011-01. 
•  FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia.  Med Oncol. 2011-01. 
•  The Outcome of Unrelated Hematopoietic Stem Cell Transplants with Total Body Irradiation (800 cGy) and Cyclophosphamide (120 mg/kg) in Adult Patients with Acquired Severe Aplastic Anemia.  Biol Blood Marrow Transplant. 2011-01. 
•  Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia.  Leukemia. 2010-12. 
•  Cytomegalovirus ventriculoencephalitis after unrelated double cord blood stem cell transplantation with an alemtuzumab-containing preparative regimen for Philadelphia-positive acute lymphoblastic leukemia.  J Korean Med Sci. 2010-04. 
•  A Study of Mixed Phenotype Acute Leukemia Based on the 2008 World Health Organization Classification.  Korean J Lab Med. 2010-06. 
•  B lymphoblastic leukemia with ETV6 amplification.  Cancer Genet Cytogenet. 2010-02. 
•  Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation.  Transplantation. 2010-08. 
•  Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.  Int J Hematol. 2010-02. 
•  The characteristics and clinical outcome of adult patients with aplastic anemia and abnormal cytogenetics at diagnosis.  Genes Chromosomes Cancer. 2010-09. 
•  Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center.  Bone Marrow Transplant. 2010-08. 
•  HLA-matched sibling transplantation with BM and CD34(+)-purified PBSCs in adult patients with high-risk severe aplastic anemia to overcome graft rejection without an increase in GVHD.  Bone Marrow Transplant. 2010-10. 
•  High levels of B-cell activating factor during the peri-transplant period are associated with the reduced incidence of acute graft-versus-host disease following the myeloablative allogeneic stem cell transplantation.  Biol Blood Marrow Transplant. 2010-05. 
•  Potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for the sustained remission of refractory AML.  Bone Marrow Transplant. 2010-03. 
•  Leukemia cutis as early relapse of T-cell acute lymphoblastic leukemia.  Int J Dermatol. 2010-03. 
•  The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.  Cancer. 2009-03. 
•  Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.  Leukemia. 2009-10. 
•  Mutational analysis of CASP10 gene in acute leukaemias and multiple myelomas.  Pathology. 2009-05. 
•  Risk factors for acute respiratory distress syndrome uring neutropenia recovery in patients with hematologic malignancies.  Crit Care. 2009-06. 
•  Bone marrow T cells are superior to splenic T cells to induce chimeric conversion after non-myeloablative bone marrow transplantation.  Korean J Intern Med. 2009-03. 
•  Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.  Jpn J Clin Oncol. 2009-07. 
•  Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.  Biol Blood Marrow Transplant. 2009-06. 
•  Overcoming various comorbidities by G-CSF-primed unmanipulated BM SCT in adult patients with AML.  Bone Marrow Transplant. 2009-06. 
•  Feasibility of NIH consensus criteria for chronic graft-versus-host disease.  Leukemia. 2009-01. 
•  Analysis of NOTCH1 extracellular juxtamembrane expansion mutations in acute leukemias and multiple myelomas.  APMIS. 2009-02. 
•  Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.  Int J Lab Hematol. 2008-06. 
•  Absence of JAK1 exon 10 and 13 mutations in acute leukemias and multiple myelomas.  Eur J Haematol. 2008-05. 
•  The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.  Am J Hematol. 2008-10. 
•  Somatic mutation of TRAF3 gene is rare in common human cancers and acute leukemias.  Acta Oncol. 2008-08. 
•  Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.  Clin Cancer Res. 2008-12. 
•  Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.  Bone Marrow Transplant. 2008-09. 
•  Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.  Biol Blood Marrow Transplant. 2007-09. 
•  Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.  Jpn J Clin Oncol. 2007-12. 
•  The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus host disease in hematopoietic stem cell transplantation for acute myelogenous leukemia.  Transplantation. 2007-09. 
•  Anti-leukaemic role of acute GvHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukaemia.  Bone Marrow Transplant. 2007-11. 
•  Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.  Eur J Haematol. 2007-05. 
•  Distribution of the minor histocompatibility antigens in Korean population and disparities in unrelated hematopoietic SCT.  Bone Marrow Transplant. 2007-08. 
•  Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.  Eur J Haematol. 2007-02. 
•  Unrelated donor bone marrow transplants for severe aplastic anemia with conditioning using total body irradiation and cyclophosphamide.  Biol Blood Marrow Transplant. 2007-07. 
•  The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome.  Int J Hematol. 2007-05. 
•  Identification of leukemia-specific fusion gene transcripts with a novel oligonucleotide array.  Mol Diagn Ther. 2007-01. 
•  Pseudomembranous colitis following bortezomib therapy in a myeloma patient.  Acta Haematol. 2007-04. 
•  The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial.  Haematologica. 2006-05. 
•  Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.  Jpn J Clin Oncol. 2006-07. 
•  Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation.  Bone Marrow Transplant. 2006-02. 
•  Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines.  Eur J Haematol. 2006-03. 
•  Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea.  Int J Hematol. 2006-03. 
•  Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse.  Bone Marrow Transplant. 2006-05. 
•  Resistant pure red cell aplasia after allogeneic bone marrow transplantation with major ABO mismatch treated by purified CD34+ cell infusion.  Eur J Haematol. 2006-02. 
•  The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.  Blood. 2005-09. 
•  Upregulated hoxC4 induces CD14 expression during the differentiation of acute promyelocytic leukemia cells.  Leukemia Lymphoma. 2005-07. 
•  Comparison of 2 preparative regimens for stem cell transplantation from HLA-matched sibling donors in patients with advanced myelodysplastic syndrome.  Int J Hematol. 2005-01. 
•  Acute promyelocytic leukemia with +der(17)t(15;17) detected by fluorescence in situ hybridization (FISH).  Ann Clin Lab Sci. 2005-02. 
•  Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea.  Int J Hematol. 2005-01. 
•  Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia.  Leukemia. 2004-11. 
•  Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.  Biol Blood Marrow Transplant. 2004-10. 
•  Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea.  Bone Marrow Transplant. 2004-06. 
•  Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.  Leukemia. 2004-09. 
•  Megadose CD34+ hemopoietic stem cell transplantation for patients with high risk acute myeloid leukemia who have no HLA matched donor - a pilot study of a full haplotype mismatch transplantation.  Korean J Intern Med. 2004-04. 
•  Spontaneous pneumothorax developed in patients with bronchiolitis obliterans after unrelated hematopoietic stem cell transplantation: case report and review of the literature.  Int J Hematol. 2004-03. 
•  Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study.  Hum Psychopharmacol. 2004-01. 
•  Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial.  Bone Marrow Transplant. 2004-05. 
•  Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.  Bone Marrow Transplant. 2004-02. 
•  Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.  Blood. 2003-08. 
•  Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction.  Br J Haematol. 2003-01. 
•  Allele frequencies of 15 STR loci using AmpF/STR Identifiler kit in a Korean population.  Forensic Sci Int. 2003-01. 
•  Bacteremic cellulitis caused by non-O1, non-O139 Vibrio cholerae in a patient following hematopoietic stem cell transplantation.  Bone Marrow Transplant. 2003-12. 
•  Influence of karyotype on outcome of allogeneic bone marrow transplantation for adults with precursor B-lineage acute lymphoblastic leukaemia in first or second remission.  Br J Haematol. 2002-01. 
•  Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood.  Int J Hematol. 2002-02. 
•  Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML.  Eur J Haematol. 2002-05. 
•  Two cases of disseminated mucormycosis in patients following allogeneic bone marrow transplantation.  J Korean Med Sci. 2002-03. 
•  Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial.  Korean J Intern Med. 2002-01. 
•  Human herpesvirus-6 as a possible cause of encephalitis and hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.  Leukemia. 2002-05. 
•  The kinetics of circulating cytokines including IL-6, TNF-, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation.  Bone Marrow Transplant. 2001-10. 
•  Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.  Bone Marrow Transplant. 2001-09. 
•  Hepatosplenic tuberculosis mimicking disseminated candidiasis in patients with acute leukemia.  Int J Hematol. 2001-01. 
•  Mobilization kinetics of CD34(+) cells in association with modulation of CD44 and CD31 expression during continuous intravenous administration of G-CSF in normal donors.  Stem Cells. 2000-04. 
•  Identification of ider[17q] in addition to t[15;17] in acute promyelocytic leukemia using whole chromosome painting probes made by interspecies hybrid using inter-Alu PCR.  Cancer Genet Cytogenet. 2000-02. 
•  Effects of intraoperative blood flow on the early patency of radiocephalic fistulas.  Ann Vasc Surg. 2000-05. 
•  Distinct patterns of apoptosis in association with modulation of CD44 induced by thrombopoietin and granulocyte-colony stimulating factor during ex vivo expansion of human cord blood CD34+ cells.  Br J Haematol. 1999-01. 
•  Delayed activation-induced T lymphocytes death in aplastic anemia: related with abnormal Fas system.  Korean J Intern Med. 1998-01. 
•  Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD.  Bone Marrow Transplant. 1997-10. 
•  Eight-year experience of malignant lymphoma-survival and prognostic factors.  Yonsei Med J. 1997-05. 
•  Monitoring of WT-1 gene expression in peripheral blood of patients with acute leukemia by semiquantitative RT-PCR; possible marker for detection of minimal residual leukemia.  Yonsei Med J. 1997-04. 
•  Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy.  Br J Haematol. 1996-04. 
•  Differential responses of CD34-positive acute myelogenous leukemic blasts to the costimulating effects of stem cell factor with GM-CSF and/or IL-3.  Yonsei Med J. 1995-01. 

• [동아일보] “국내 암 발병 중 0.4%가 급성백혈병… 완치율은 평균 60%” 2025-08-13
• [동아일보] “갑자기 빈혈에 잇몸 출혈 안 멈춘다면 의심을” 2025-02-15
• [약업신문] 블린사이토, 재발·불응성 혈액암서 치료 옵션 제공중 2024-12-06
• [메디칼업저버] 이대목동, 백혈병 치료 권위자 이석 교수 영입 2024-12-02

• [건강강좌영상] 성인 급성림프구백혈병, 완치를 향한 최신 치료법은? 2025-07-29